HIKMA Pharmaceuticals PLC — Major Shareholding Notification 2016

Feb 29, 2016

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 4959Q

Hikma Pharmaceuticals Plc

29 February 2016

For filings with the FCA include the annex
For filings with issuer exclude the annex
TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi
1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: ii				Hikma Pharmaceuticals PLC
2 Reason for the notification (please tick the appropriate box or boxes):
An acquisition or disposal of voting rights					ü
An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached
An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments
An event changing the breakdown of voting rights
Other (please specify):
3. Full name of person(s) subject to the notification obligation: iii		Boehringer Ingelheim Corporation; Boehringer Ingelheim USA Corporation; Boehringer Ingelheim Auslandsbeteiligungs GmbH; Boehringer Ingelheim International GmbH; Boehringer Ingelheim Verwaltungs GmbH; Dr. Karl Thomae GmbH; C.H. Boehringer Sohn AG & Co. KG
4. Full name of shareholder(s) (if different from 3.):iv		Boehringer Ingelheim Corporation
5. Date of the transaction and date on which the threshold is crossed or reached: v		29 February 2016
6. Date on which issuer notified:		29 February 2016
7. Threshold(s) that is/are crossed or reached: vi, vii		16%

8. Notified details:
A: Voting rights attached to shares viii, ix
Class/type of shares if possible using the ISIN CODE	Situation previous to the triggering transaction						Resulting situation after the triggering transaction
Number of Shares			Number of Voting Rights			Number of shares		Number of voting rights			% of  voting rights x
Indirect		Direct xi		Indirect xii	Direct	Indirect
GB00B0LCW083	0			0			40,000,000		40,000,000		0	16.67%	0
B: Qualifying Financial Instruments
Resulting situation after the triggering transaction
Type of financial instrument			Expiration date xiii		Exercise/ Conversion Period xiv					Number of voting rights that may be acquired if the instrument is exercised/ converted.		% of voting rights
C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi
Resulting situation after the triggering transaction
Type of financial instrument		Exercise price		Expiration date xvii		Exercise/ Conversion period xviii		Number of voting rights instrument refers to				% of voting rights xix, xx
												Nominal		Delta
Total (A+B+C)
Number of voting rights								Percentage of voting rights
40,000,000								16.67%
9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable: xxi
Boehringer Ingelheim Corporation has the following parent undertakings: Boehringer Ingelheim USA Corporation, a Delaware corporation (wholly owns the voting shares in Boehringer Ingelheim Corporation). Boehringer Ingelheim Auslandsbeteiligungs GmbH, a German company with limited liability (wholly owns Boehringer Ingelheim USA Corporation). Boehringer Ingelheim International GmbH, a German company with limited liability (wholly owns Boehringer Ingelheim Auslandsbeteiligungs GmbH). Boehringer Ingelheim Verwaltungs GmbH, a German company with limited liability (wholly owns Boehringer Ingelheim International GmbH). Dr. Karl Thomae GmbH, a German company with limited liability (wholly owns Boehringer Ingelheim Verwaltungs GmbH). C.H. Boehringer Sohn AG & Co. KG, a German limited partnership (wholly owns Dr. Karl Thomae GmbH).
Proxy Voting:
10. Name of the proxy holder:											N/A
11. Number of voting rights proxy holder will acquire:
12. Date on which proxy holder will acquire voting rights:
13. Additional information:								None
14. Contact name:								Stephan Bach (Corporate Treasury) Eric Humbert (Corporate Treasury)
15. Contact telephone number:								Stephan Bach: +49 (6132) 77-3032 Eric Humbert:  +49 (6132) 77-90717

This information is provided by RNS

The company news service from the London Stock Exchange

END

HOLUKVORNWAUUAR